These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 15581945)

  • 1. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
    Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
    Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein.
    Abdollahi A; Bao R; Hamilton TC
    Oncogene; 1999 Nov; 18(47):6477-87. PubMed ID: 10597250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck.
    Koy S; Hauses M; Appelt H; Friedrich K; Schackert HK; Eckelt U
    Head Neck; 2004 Apr; 26(4):338-44. PubMed ID: 15054737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive role of the metastasis-related nm23-H1 gene in human ovarian carcinomas: association of high messenger RNA expression with lack of lymph node metastasis.
    Viel A; Dall'Agnese L; Canzonieri V; Sopracordevole F; Capozzi E; Carbone A; Visentin MC; Boiocchi M
    Cancer Res; 1995 Jun; 55(12):2645-50. PubMed ID: 7780979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors.
    Bilanges B; Varrault A; Basyuk E; Rodriguez C; Mazumdar A; Pantaloni C; Bockaert J; Theillet C; Spengler D; Journot L
    Oncogene; 1999 Jul; 18(27):3979-88. PubMed ID: 10435621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.
    Gorringe KL; Ramakrishna M; Williams LH; Sridhar A; Boyle SE; Bearfoot JL; Li J; Anglesio MS; Campbell IG
    Genes Chromosomes Cancer; 2009 Oct; 48(10):931-42. PubMed ID: 19603523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
    Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
    Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer.
    Abdollahi A; Pisarcik D; Roberts D; Weinstein J; Cairns P; Hamilton TC
    J Biol Chem; 2003 Feb; 278(8):6041-9. PubMed ID: 12473647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer.
    Tangir J; Muto MG; Berkowitz RS; Welch WR; Bell DA; Mok SC
    Oncogene; 1996 Feb; 12(4):735-40. PubMed ID: 8632895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LOT1 (ZAC1/PLAGL1) and its family members: mechanisms and functions.
    Abdollahi A
    J Cell Physiol; 2007 Jan; 210(1):16-25. PubMed ID: 17063461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
    Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
    Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel 4 cM minimal deletion unit on chromosome 6q25.1-q25.2 associated with high grade invasive epithelial ovarian carcinomas.
    Colitti CV; Rodabaugh KJ; Welch WR; Berkowitz RS; Mok SC
    Oncogene; 1998 Jan; 16(4):555-9. PubMed ID: 9484846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma.
    Liu FS; Dong JT; Chen JT; Hsieh YT; Ho ES; Hung MJ
    Gynecol Oncol; 2000 Jul; 78(1):10-5. PubMed ID: 10873402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allelic loss on chromosome arm 8p: analysis of sporadic epithelial ovarian tumors.
    Brown MR; Chuaqui R; Vocke CD; Berchuck A; Middleton LP; Emmert-Buck MR; Kohn EC
    Gynecol Oncol; 1999 Jul; 74(1):98-102. PubMed ID: 10385558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.
    Filippova GN; Lindblom A; Meincke LJ; Klenova EM; Neiman PE; Collins SJ; Doggett NA; Lobanenkov VV
    Genes Chromosomes Cancer; 1998 May; 22(1):26-36. PubMed ID: 9591631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas.
    Gunduz M; Nagatsuka H; Demircan K; Gunduz E; Cengiz B; Ouchida M; Tsujigiwa H; Yamachika E; Fukushima K; Beder L; Hirohata S; Ninomiya Y; Nishizaki K; Shimizu K; Nagai N
    Gene; 2005 Aug; 356():109-17. PubMed ID: 15935570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters.
    Phelan CM; Borg A; Cuny M; Crichton DN; Baldersson T; Andersen TI; Caligo MA; Lidereau R; Lindblom A; Seitz S; Kelsell D; Hamann U; Rio P; Thorlacius S; Papp J; Olah E; Ponder B; Bignon YJ; Scherneck S; Barkardottir R; Borresen-Dale AL; Eyfjörd J; Theillet C; Thompson AM; Larsson C
    Cancer Res; 1998 Mar; 58(5):1004-12. PubMed ID: 9500463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of heterozygosity at chromosome segment Xq25-26.1 in advanced human ovarian carcinomas.
    Choi C; Cho S; Horikawa I; Berchuck A; Wang N; Cedrone E; Jhung SW; Lee JB; Kerr J; Chenevix-Trench G; Kim S; Barrett JC; Koi M
    Genes Chromosomes Cancer; 1997 Nov; 20(3):234-42. PubMed ID: 9365830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.